Letrozole is a aromatase Inhibitor. It is used in the treatment of breast cancer. inhibits the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization

Imatinib is a tyrosine kinase inhibitor. It inhibits the activity of the  Bcr-Abl tyrosine kinase (TK)

Sorafenib is a tyrosine kinase inhibitor, Angiogenesis Inhibitor and VEGF inhibitor. It inhibits multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases 

Nilotinib is a tyrosine kinase inhibitor. It inhibits the ABL tyrosine kinase activity of the BCR-ABL oncoprotein both in cell lines and in primary Philadelphia-chromosome positive leukaemia cells

Erlotinib is a tyrosine kinase inhibitor, epidermal growth factor receptor inhibitor, EGFR inhibitor and EGF receptor inhibitor. It inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal

Sunitinib is a multi-receptor tyrosine kinase (RTK) inhibitor. It inhibits CD117 (c-KIT) , the receptor tyrosine kinase and all receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors

Gefitinib is a tyrosine kinase inhibitor. It inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme

Palbociclib is a cyclin-dependent kinase 4/6 inhibitor or CDK4/6 inhibitor.it is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, that acts by binding to the ATP pocket with an IC50

Ibrutinib is a burton’s tyrosine kinase inhibitor. it forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity

Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma

Pazopanib is a multi-receptor tyrosine kinase inhibitor. It inhibits multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor

Regorafenib is a multiple receptor tyrosine kinase inhibitor. It inhibits the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAF 

Dasatinib is a tyrosine kinase inhibitor. It inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ.

Dasatinib is a tyrosine kinase inhibitor. It inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ

Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2, and EGFR; TKI inhibition blocks angiogenesis and cellular proliferation

Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of 

Crizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor.